Morphic Holding, Inc. (NASDAQ:MORF) CAO Sells $198,215.49 in Stock

Morphic Holding, Inc. (NASDAQ:MORF) CAO Robert E. Farrell, Jr. sold 3,049 shares of the business’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $65.01, for a total value of $198,215.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Morphic stock traded up $1.38 on Tuesday, reaching $66.86. The company’s stock had a trading volume of 163,615 shares, compared to its average volume of 275,257. The company has a market cap of $2.44 billion, a price-to-earnings ratio of -37.14 and a beta of 1.20. The business’s fifty day moving average price is $59.96 and its 200 day moving average price is $58.66. Morphic Holding, Inc. has a twelve month low of $24.52 and a twelve month high of $93.00.

Morphic (NASDAQ:MORF) last posted its quarterly earnings data on Wednesday, August 4th. The company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.22). The business had revenue of $3.85 million during the quarter, compared to analyst estimates of $5.80 million. Morphic had a negative return on equity of 24.79% and a negative net margin of 158.61%. Morphic’s quarterly revenue was down 50.0% compared to the same quarter last year. As a group, equities research analysts forecast that Morphic Holding, Inc. will post -3.01 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in Morphic by 0.8% in the second quarter. Wells Fargo & Company MN now owns 48,694 shares of the company’s stock worth $2,794,000 after purchasing an additional 387 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Morphic by 34.4% during the second quarter. Ameritas Investment Partners Inc. now owns 1,626 shares of the company’s stock valued at $93,000 after acquiring an additional 416 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of Morphic by 8.2% during the second quarter. Parametric Portfolio Associates LLC now owns 5,928 shares of the company’s stock valued at $340,000 after acquiring an additional 451 shares during the period. Credit Suisse AG lifted its stake in shares of Morphic by 5.1% during the second quarter. Credit Suisse AG now owns 10,979 shares of the company’s stock valued at $630,000 after acquiring an additional 534 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Morphic by 5.5% during the second quarter. AQR Capital Management LLC now owns 11,604 shares of the company’s stock valued at $666,000 after acquiring an additional 606 shares during the period. 71.77% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research lowered Morphic from a “hold” rating to a “sell” rating in a research note on Friday, August 6th.

Morphic Company Profile

Morphic Holding, Inc operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A.

Further Reading: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for Morphic (NASDAQ:MORF)

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.